Evidence map›Paper›PMID 34971849›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2022

Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses.

Anbalagan Anantharaj, Sunil Gujjar, Nikhil Verma, Naseem Ahmed Khan, Heena Shaman, Patil Sharanabasava, Asim Das, Rajesh Pandey, Anil Kumar Pandey, Guruprasad R Medigeshi

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Anbalagan AnantharajBioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana. India.
Sunil GujjarClinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana. India.
Nikhil VermaEmployees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India.
Naseem Ahmed KhanBioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana. India.
Heena ShamanBioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana. India.
Patil SharanabasavaBioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana. India.
Asim DasEmployees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India.
Rajesh PandeyCSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Anil Kumar PandeyEmployees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India.
Guruprasad R MedigeshiBioassay Laboratory, Translational Health Science and Technology Institute, Faridabad, Haryana. India; Clinical and Cellular Virology lab, Translational Health Science and Technology Institute, Faridabad, Haryana. India. Electronic address: gmedigeshi@thsti.res.in.
Translational Health Science and Technology Institute · INEmployees' State Insurance Model Hospital · INInstitute of Genomics and Integrative Biology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 90% of the COVID-19 patients manifest mild/moderate symptoms or are asymptomatic. Although comorbidities and dysregulation of immune response have been implicated in severe COVID-19, the host factors that associate with asymptomatic or mild infections have not been characterized. We have collected serial samples from 23 hospitalized COVID-19 patients with mild symptoms and measured the kinetics of SARS-CoV-2 viral load in respiratory samples and markers of inflammation in serum samples. We monitored seroconversion during the acute phase of illness and quantitated the amount of total IgG against the receptor-binding domain of SARS-CoV-2 and estimated the virus neutralization potential of these antibodies. Viral load decreased by day 8 in all the patients but the detection of viral RNA in saliva samples did not correlate well with viral RNA detection in nasopharyngeal/oropharyngeal swab samples. 25% of the virus-positive patients had no detectable neutralizing antibodies in the serum and in other cases, the efficiency of antibodies to neutralize SARS-CoV-2 B1.1.7 strain was lower as compared to the circulating virus isolate. Decrease in viral load coincided with increase in neutralizing antibodies and interferon levels in serum. Most patients showed no increase in inflammatory cytokines such as IL-1β or IL-6, however, elevated levels of IL-7 and other inflammatory mediators such as TNF-α and IL-8 was observed. These data suggest that most mild infections are associated with absence of inflammation coupled with an active innate immune response, T-cell activation and neutralizing antibodies.

Indexed as

COVID-19Antibodies, ViralHumansImmunitySARS-CoV-2Viral LoadAntibodies, ViralAntibodiesCOVID-19CytokinesInflammationPRNTSARS-CoV-2

Identifiers

PMID34971849
PMCPMC8687718
OpenAlexW4200008686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.